MedTrace Logo

The Incretin Effect in Patients With Chronic Pancreatitis

NCT00638573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2010-01-13

No results posted yet for this study

Summary

The phenomenon that oral glucose elicits a higher insulin response than does intravenous (iv) glucose, even at identical plasma glucose (PG) profiles (isoglycemia), is called the incretin effect. In type 2 diabetes mellitus (T2DM) the incretin effect has been shown to be markedly reduced or even abolished. It is not known whether the reduced incretin effect in T2DM is a primary event leading to T2DM or if it is merely a consequence of the diabetic state. To answer this question the investigators plan to estimate the incretin effect in 8 patients with secondary diabetes mellitus (DM) to chronic pancreatitis (CP) and compare it to the incretin effect of 8 patients with CP and normal glucose tolerance (NGT). Eight patients with T2DM and 8 healthy control subjects are studied for comparison. The incretin effect is measured by a 50-g oral glucose tolerance test and an isoglycemic intravenous glucose infusion.

Conditions

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD · University of Copenhagen

  • Jens J Holst, MD DMSc · University of Copenhagen

  • Thure Krarup, MD DMSc · Gentofte University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Completion
2006-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638573 on ClinicalTrials.gov